All News

smiley-2979107_640_0.jpg

Self-Directed Cognitive Behavioral Therapy for Chronic Pain

Jack Cush, MD

Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP?

Read Article
guidelines.recommendations.jpg

2026 Guidelines for the Treatment of Axial Spondyloarthritis

ACR

New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children.

Read Article
RA,Rx,puzzle

EULAR26: Pitfalls in Treat-to-Target

EurekAlert!

Real-world or observational data from registries, claims datasets, or electronic health records can enable us to perform large-scale analyses.

Read Article
Blood labs

2-Gene Blood Test for Kawasaki Disease in Febrile Children

Jack Cush, MD

JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses. 

Read Article
B CELL DEPLETION

B cell Targeting in SLE

MedPage Today

Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.

Read Article
pregnancy,embryo,fetal

No Fetal Risks with First Trimester NSAID Use

Jack Cush, MD

PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital malformatoin (MCM) risk. 

Read Article
Up to 80% of Brucellosis has MSK Sxs (half in the spine/SI). CDC reports in the USA 2010–2024 1,796 confirmed and probable cases - 61% reported travel (80% Intl travel). Most exposures consumed unpasteurized dairy products or undercooked meat 73%], 62% had animal contact and 40% https://t.co/Njpf71jwKd
Dr. John Cush RheumNow ( View Tweet)
4-week, proof-of-concept, PBO-controlled RCT Rx 30 Depression pts w/ either PBO or tocilizumab. No improvement by day 14, but over time TCZ pts improved depressive Sxs & severity, fatigue, anxiety, & QOL. Remission seen in 54% vs 31%, favoring TCZ. https://t.co/FpdZJikf8C https://t.co/IaKP3JXARa

Links:

Dr. John Cush RheumNow ( View Tweet)
Redefining axial spondyloarthritis An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need." https://t.co/6uLv16aOcX https://t.co/a3NxMdnI9F

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST POLL> ?How valuable is a Lupus Nephritis Indication when treating NON-RENAL lupus? Answer here>> https://t.co/K4aikzZRmY https://t.co/60wM3XJE8n

Links:

Dr. John Cush RheumNow ( View Tweet)
No Fetal Risks with First Trimester NSAID Use PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital https://t.co/ZVUOizbcdg
Dr. John Cush RheumNow ( View Tweet)
Steroids in SpA? DBRPCT of 94 (nonPsA) SpA pts w/ peripheral arthritis (SJC ≥ 2) placebo or steroids (GC) (csDMARDs background allowed). 76% male, age 32 yrs, TJC 10, SJC 3.6. Wk 24 there was no signif diff betw groups for ACR 50, ACR70 or PSpARC outcomes. https://t.co/snJovW31Uk
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 116 BL KOA (Kellgren–Lawrence I–II) pts rx w/ three PRP injx (n 58) or NSAIDs +/- IAhyaluronic acid (n 58). After 5 yrs there was no signif. difference in VAS, WOMAC, and SF-36, with both groups worsening. https://t.co/KDSMTvEl59 https://t.co/lgHOsppIU3

Links:

Dr. John Cush RheumNow ( View Tweet)
Mentors & Mentees can do great things!!! https://t.co/gdf5laCuCm

Links:

Dr. John Cush RheumNow ( View Tweet)

Chinese study of 341 RA pts, half managed post D/C w/ nurse led AI interactive platform vs usual care. @ 6 mos AI platform group had signif better outcomes - DAS28 (-0.77 vs -0.27), HAQ functional status, medication adherence (90 vs 80%), and pt satisfaction (96 vs 76%) https://t.co/SrDgUuAWB3
Dr. John Cush RheumNow ( View Tweet)
Korean insurance claims study of 50 600 adults w/ newly dx #RA - Persistent low-income significantly increased mortality risk, especially if RA <65 yrs or rural residence; Sustained high-income status provided a protective effect across all age group https://t.co/OIhvz489Ar https://t.co/lYwgc2Ty3n

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA Review on Low Back Pain A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain (nsLBP), drawing on 108 publications identified from a PubMed search (2005–2026) and the https://t.co/liEitQ2ACf
Dr. John Cush RheumNow ( View Tweet)
Can AI Predict Progression to RA? Dr. Jonathan Kay reports on abstract POS0967 at EULAR 2026 in London https://t.co/m8wvp93mTA https://t.co/ADZa9C4068

Links:

Dr. John Cush RheumNow ( View Tweet)
Do You Zoster Vaccinate? (6.19.2026) Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026. https://t.co/hOfXR39s3H https://t.co/X7skwKrCc3

Links:

Dr. John Cush RheumNow ( View Tweet)
Missed a session at EULAR 2026? No problem. The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/YZ7oRNXfqU
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×